Search Results | Blood | American Society of Hematology

1-20 of 315

Sort by

Sort Order Select

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

DOI: https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Long-Term Hydroxyurea Use Is Associated with Lower Levels of Hematopoietic Stem and Progenitor Cells in Patients with Sickle Cell Disease

Seda S. Tolu, MD, Kai Wang, PhD, Zi Yan, Andrew Crouch, Gracy Sebastian, NP, Mark Chaitowitz, MD, Eric Fornari, MD, Evan Schwechter, MD, Joan Uehlinger, MD, Deepa Manwani, MD, Caterina P. Minniti, MD, Eric E. Bouhassira, PhD

Blood (2019) 134 (Supplement_1): 985.

DOI: https://doi.org/10.1182/blood-2019-131648

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Blood (2019) 134 (Supplement_1): 1302.

DOI: https://doi.org/10.1182/blood-2019-124882

Published: 2019

Journal Articles

Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study

Adam J Olszewski, MD, Matthew S. Davids, MD, Inna Yakirevich, NP, Pamela C Egan, MD

Blood (2019) 134 (Supplement_1): 265.

DOI: https://doi.org/10.1182/blood-2019-122516

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

DOI: https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

DOI: https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

DOI: https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Dina Sameh Soliman, MD MB, MMSc, Ahmed Al-Sabbagh, MD, Shehab Fareed Mohamed, MD, Susanna Jane Akiki, PhD, Halima El-Omri, MD, Firyal Ibrahim, MD, Mohamed A Yassin, MBBS, MSc, Prem Chandra, PhD

Blood (2019) 134 (Supplement_1): 5169.

DOI: https://doi.org/10.1182/blood-2019-124951

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

DOI: https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Daisuke Hidaka, Masahiro Onozawa, Naohiro Miyashita, Masao Nakagawa, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 3369.

DOI: https://doi.org/10.1182/blood-2019-122999

Published: 2019

Journal Articles

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Ayad Al-Katib, MD, Ebrahim Abdul Shukkur, PhD, Ali M Gabali, MD PhD, ALI Raufi, MD, Salah Ebrahim, MD, Mustapha Kandouz, PhD

Blood (2019) 134 (Supplement_1): 3970.

DOI: https://doi.org/10.1182/blood-2019-130738

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

DOI: https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

DOI: https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Yoshiyuki Ogawa, MD PhD, Kunio Yanagisawa, MD PhD, Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Akitada Ichinose, MD PhD, Hiroshi Handa, MD PhD

Blood (2018) 132 (Supplement 1): 2497.

DOI: https://doi.org/10.1182/blood-2018-99-112126

Published: 2018

Journal Articles

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

Rao Mushtaq, MD, Faisal Akbar, MBBS, MD, Israa Khan, MD, Scott Isom, M.S., Timothy Pardee, MD PhD, Dianna S. Howard, MD, Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 5199.

DOI: https://doi.org/10.1182/blood-2018-99-110191

Published: 2018

Journal Articles

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Tiziano Barbui, MD, Arianna Ghirardi, PhD, Arianna Masciulli, PhD, Alessandra Carobbio, MSc, Francesca Palandri, PhD MD, Nicola Vianelli, MD, Valerio De Stefano, MD, Silvia Betti, MD, Ambra Di Veroli, MD, Alessandra Iurlo, Daniele Cattaneo, MD, Federica Delaini, MSc, Massimiliano Bonifacio, MD, Luigi Scaffidi, MD, Andrea Patriarca, MD, Elisa Rumi, MD, Clemency Stephenson, MD, Paola Guglielmelli, MD PhD, Elena Maria Elli, MD, Palova Miroslava, MD, Laura Bertolotti, MSc, Daniel Erez, MD, Montse Gomez, MD, Kai Wille, MD, Manuel Pérez-Encinas, MD, Francesca Lunghi, Anna Angola Figueras, MD, Maria Laura Fox, MD, Eloise Beggiato, MD, Giulia Benevolo, MD, Giuseppe Carli, MD, Rossella Rosari Cacciola, Mary Frances McMullin, MD, Alessia Tieghi, MD, Valle Recanses Flores, MD, Monia Marchetti, Martin Griesshammer, MD PhD, Alberto Alvarez-Larran, MD, Alessandro M. Vannucchi, MD, Guido Finazzi, MD

Blood (2018) 132 (Supplement 1): 4279.

DOI: https://doi.org/10.1182/blood-2018-99-112387

Published: 2018

Journal Articles

Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine

Jiawei Wang, Lian Li, PhD, Jiyuan Yang, PhD, Phillip M. Clair, MS, Martha Glenn, MD, Deborah M. Stephens, D. Christopher Radford, PhDCandidate, Ken M. Kosak, Michael W. Deininger, MD PhD, Paul J Shami, MD, Jindřich Kopeček, PhD

Blood (2018) 132 (Supplement 1): 4426.

DOI: https://doi.org/10.1182/blood-2018-99-112001

Published: 2018

Journal Articles

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Charlotte Calvo, Benoit Brethon, Aurelie Cabannes-Hamy, MD, Dalila Adjaoud, MD, Benedicte Bruno, MD, Laurence Blanc, MD, Nicolas Boissel, MD PhD, Marie-Dominique Tabone, MD, Andre Baruchel, MD

Blood (2018) 132 (Supplement 1): 5203.

DOI: https://doi.org/10.1182/blood-2018-99-116360

Published: 2018

Journal Articles

Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis

Rajshekhar Chakraborty, MBBS, Saad Ullah Malik, Naimisha Marneni, Alex V. Mejia Garcia, MD, Faiz Anwer, MD, Alok A. Khorana, MD, Navneet S. Majhail, MD MS

Blood (2018) 132 (Supplement 1): 4835.

DOI: https://doi.org/10.1182/blood-2018-99-117386

Published: 2018

Journal Articles

ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin

Roya Rafiee, PhD, Soheil Meshinchi, MD PhD, Jatinder K Lamba, PhD

Blood (2018) 132 (Supplement 1): 1364.

DOI: https://doi.org/10.1182/blood-2018-99-119648

Published: 2018

NARROW

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Long-Term Hydroxyurea Use Is Associated with Lower Levels of Hematopoietic Stem and Progenitor Cells in Patients with Sickle Cell Disease

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine

Inotuzumab Ozogamicin Compassionate Use for French Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis

ABCB1 rs1045642 C>T Change Is Associated with AML Cell Line Sensitivity to Calicheamicin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only